Table 2.
Univariate and multivariate Cox regression analysis for prediction of PFS after RC for NSCLC.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Hazard ratio (95%CI) | P-value | Hazard ratio (95%CI) | P-value | |
| Gender, n (%) | 0.003 | 0.939 | ||
| Male | Ref | Ref | ||
| Female | 1.530 (1.151-2.034) | 0.986 (0.694-1.401) | ||
| Age(years) | 0.002 | 0.045 | ||
| <60 | Ref | Ref | ||
| ≥60 | 0.785 (0.675-0.914) | 1.379 (1.008-1.886) | ||
| Smoking, n (%) | 0.001 | 0.050 | ||
| Yes | Ref | Ref | ||
| No | 0.794 (0.690-0.914) | 1.409 (0.999-1.986) | ||
| Tumor size, cm | <0.001 | 0.024 | ||
| ≤5 | Ref | Ref | ||
| >5 | 1.519 (1.307-1.764) | 1.636 (1.069-2.505) | ||
| TNM, n (%) | <0.001 | <0.001 | ||
| LG | Ref | Ref | ||
| HG | 0.224 (0.165-0.304) | 0.493 (0.334-0.726) | ||
| Microvascular invasion | <0.001 | 0.005 | ||
| Yes | Ref | Ref | ||
| No | 0.564 (0.487-0.652) | 1.597 (1.151-2.215) | ||
| Ki67 (%) | <0.001 | <0.001 | ||
| <15 | Ref | Ref | ||
| ≥15 | 0.264 (0.192-0.362) | 2.173 (1.530-3.086) | ||
| Adjuvant Therapy*, n | <0.001 | 0.080 | ||
| (%) | ||||
| Yes | Ref | Ref | ||
| No | 2.045 (1.544-2.709) | 0.760 (0.559-1.034) | ||
| WBC (x109/L) | 0.492 | |||
| <5.775 | Ref | |||
| ≥5.775 | 0.890 (0.638-1.241) | |||
| PLT (x109/L) | 0.001 | 0.009 | ||
| <234.5 | Ref | Ref | ||
| ≥234.5 | 0.610 (0.458-0.813) | 1.565 (1.119-2.188) | ||
| PLT2 (x109/L) | <0.001 | 0.551 | ||
| <253.5 | Ref | Ref | ||
| ≥253.5 | 0.431 (0.323-0.575) | 1.120 (0.772-1.624) | ||
| PPR | <0.001 | 0.039 | ||
| <1.21 | Ref | Ref | ||
| ≥1.21 | 0.481 (0.363-0.638) | 1.452 (1.019-2.069) | ||
Abbreviation: CI, confidence interval; HG, high grade; NSCLC, non-small cell lung cancer; TNM, tumor Node Metastasis; WBC, white blood cell; PLT, preoperative platelet; PLT2, postoperative platelet; PPR, postoperative platelet/preoperative platelet ratio; Ref, reference. * Adjuvant radiotherapy and/or adjuvant chemotherapy.